Factors affecting 223Ra therapy : clinical experience after 532 cycles from a single institution

Factors affecting 223Ra therapy : clinical experience after 532 cycles from a single institution

Elba C. Etchebehere, Denai R. Milton, John C. Araujo, Nancy M. Swanston, Homer A. Macapinlac, Eric M. Rohren

ARTIGO

Inglês

Purpose The aim of this study was to identify baseline features that predict outcome in Ra-223 therapy.
Methods We retrospectively reviewed 110 patients with metastatic castration-resistant prostate cancer treated with Ra-223. End points were overall survival (OS), progression-free survival (PFS),...

FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP

Fechado

Factors affecting 223Ra therapy : clinical experience after 532 cycles from a single institution

Elba C. Etchebehere, Denai R. Milton, John C. Araujo, Nancy M. Swanston, Homer A. Macapinlac, Eric M. Rohren


										

Factors affecting 223Ra therapy : clinical experience after 532 cycles from a single institution

Elba C. Etchebehere, Denai R. Milton, John C. Araujo, Nancy M. Swanston, Homer A. Macapinlac, Eric M. Rohren

    Fontes

    European journal of nuclear medicine and molecular imaging

    Vol. 43, no. 1 (Jan., 2016), p. 8-20